Startup · $26.4m raised
Perth, WA
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Respirion raised.
| Investor | Rounds | Invested |
|---|---|---|
| MRCF-BTF | Unnamed stage | $20,000,000 |
| US Cystic Fibrosis Foundation | Grant | $4,230,000 |
| Innovation Seed Fund | Grant | - |
| WA Future Health Research and Innovation Fund | Grant | - |
| Brandon BioCatalyst | Accelerator · Grant | - |
| Brandon Capital Partners | Unnamed stage | - |
Investors whose own portfolio pages list Respirion, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
Companies Respirion acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Barry Clements | Founder and Director | Brandon Capital, Startup Daily, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Dr Kath Giles | Director | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Respirion. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's blog profiles Respirion, interviewing founders Barry Clements and Matt Callahan plus investment manager Helga Mikkelsen about the company's inhaled cystic fibrosis therapy, now in a Phase 2a trial.
A weekly roundup of funding deals by Australian and New Zealand startups, spanning baked goods, retail, health AI, beverages, edtech, solar, legal tech, and Western Australian medical research grants.
Also Startup Daily
WA's Innovation Seed Fund has awarded almost $5 million in grants to 12 researchers and startups for health projects, from liver cancer tests to endometriosis diagnosis, ranging from $90,000 to $500,000.
A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.
A Telethon Kids offshoot, Respirion Pharmaceuticals, is trialling its antibiotic-booster therapy RSP-1502 in the US and Australia, with backing from Brandon Capital and an American cystic fibrosis foundation.
CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.
Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia
The industry minister announced Biomedical Translation Fund backing: Brandon Capital invested $20 million in Respirion, OneVentures $4 million in Madorra, and $17.2 million went to an unnamed anti-fibrosis drug company.
The MRCF Biomedical Translation Fund has launched Respirion Pharmaceuticals, a Perth biotech developing an inhaled antibiotic for cystic fibrosis, committing up to A$20 million, with up to US$3 million from the CF Foundation.